Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield Maine Abraxane Coverage Upd…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MainePolicy CC-0099

    Abraxane (paclitaxel, protein bound) — Clinical Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Maine Policy CC-0099 alerts

    Get alerted when Policy CC-0099 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria for use of Abraxane (protein/albumin-bound paclitaxel) across oncology indications; governs prior authorization and medical necessity determinations for members.

    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyAbraxane (paclitaxel, protein bound) — Clinical Coverage Criteria
    Policy CodePolicy CC-0099
    Change TypeNCCN/FDA alignmentcoding and indication additions
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateJun 8, 2026
    Key ActionSubmit prior authorization with indication, relevant ICD-10 diagnosis code, ECOG status, prior therapies, and laboratory documentation (including baseline blood counts).
    SourceLink
    POLICY UPDATE CHANGES

    Add FDA use in combination with LifyoRli for platinum-resistant ovarian cancer.

    Add NCCN 2A criteria for use as fourth-line therapy and beyond in HER2 positive breast cancer.

    Clarified multiple NCCN disease-state criteria (melanoma, uveal melanoma, Kaposi sarcoma, endometrial, biliary tract) and removed maintenance therapy for pancreatic adenocarcinoma.

    Coding updates: added ICD-10-CM codes to breast cancer range C50.011-C50.929 and previously added/removed various HCPCS codes across prior years.

    ≈20Distinct indications listed
    NCCN cited

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NCCN guideline references
    0-2ECOG requirement
    Black boxNeutropenia contraindication
    1HCPCS J9264
    2026-06-08Last review

    Coverage Criteria for Abraxane (paclitaxel, protein bound)

    Approved Indications and Required Conditions

    Requests may be approved when ANY one of the following indication-specific groups is met

    Age under 19: Individual is under 19 years of age
    Breast cancer - single agent after prior combo chemo: Individual has a diagnosis of breast cancer AND is using Abraxane as a single agent after failure on combination chemotherapy for metastatic disease or relapsed within 6 months of adjuvant therapy (Label) AND individual has had previous chemotherapy including an anthracycline unless clinically contraindicated
    Breast cancer - recurrent unresectable or metastatic HER2-negative: Individual has recurrent unresectable or metastatic (stage IV) HER2-negative breast cancer AND is using Abraxane as a single agent or in combination with carboplatin AND disease is hormone receptor–positive and refractory to endocrine therapy or presents with visceral crisis

    (NCCN 2A)

    Breast cancer - triple negative high burden: Individual has triple-negative breast cancer with high tumor burden, rapidly progressing disease, or visceral crisis AND is using Abraxane as a single agent or in combination with carboplatin AND use is either first-line if PD-L1 < 10 and no germline BRCA1/2 mutation (NCCN 1) OR second-line and beyond

    (NCCN 2A)

    Breast cancer - PD-L1 positive TNBC with pembrolizumab: Individual has PD-L1–positive triple-negative breast cancer AND is using Abraxane in combination with pembrolizumab AND use is either first-line therapy (NCCN 1) OR second and subsequent lines if a PD‑1/PD‑L1 inhibitor has not previously been used (NCCN 2A)
    Breast cancer - HER2 positive fourth-line+: Individual has HER2‑positive breast cancer AND is using Abraxane as fourth‑line therapy and beyond in combination with trastuzumab (or trastuzumab biosimilar)

    (NCCN 2A)

    Taxane hypersensitivity - breast/solid tumors: Treatment of any breast cancer or other solid tumor when taxane therapy is appropriate and the individual has confirmed hypersensitivity to solvent‑based paclitaxel or docetaxel (NCCN 2A)
    Cervical cancer - recurrent/metastatic: Individual has recurrent unresectable or metastatic cervical cancer AND is using Abraxane as second‑line or subsequent therapy AND as a single agent

    (NCCN 2A)

    Melanoma (cutaneous): Individual has metastatic or unresectable cutaneous melanoma AND is using Abraxane as a single agent or in combination with carboplatin AND as second‑line or subsequent therapy AND has ECOG performance status 0‑2ECOG 0-2

    (NCCN 2A)

    Uveal melanoma: Individual has unresectable or metastatic uveal melanoma AND is using Abraxane as single‑agent therapy

    (NCCN 2A)

    Kaposi sarcoma: Individual has Kaposi sarcoma AND is paclitaxel intolerant AND has relapsed/refractory advanced disease AND is using Abraxane as subsequent systemic therapy and as a single agent OR is using Abraxane for KICS in combination with rituximab (or biosimilar)

    (NCCN 2A)

    NSCLC - single agent for first progression: Individual has recurrent, advanced, or metastatic NSCLC AND is using Abraxane as a single agent for first progression after initial systemic therapy (if not already given) AND has ECOG performance status 0‑2ECOG 0-2

    (NCCN 2A)

    NSCLC - squamous first-line with pembrolizumab and carboplatin: Individual has recurrent, advanced, or metastatic squamous NSCLC AND is using Abraxane as first‑line therapy in combination with pembrolizumab and carboplatin AND has ECOG performance status 0‑2ECOG 0-2

    (NCCN 1, 2A)

    NSCLC - nonsquamous first-line with atezolizumab and carboplatin: Individual has recurrent, advanced, or metastatic nonsquamous NSCLC AND is using Abraxane as first‑line therapy in combination with atezolizumab and carboplatin AND has ECOG performance status 0‑2ECOG 0-2

    (NCCN 2A)

    NSCLC - subsequent after targeted therapy: Individual has recurrent, advanced, or metastatic nonsquamous NSCLC AND is using Abraxane as subsequent therapy after failure of a kinase inhibitor targeted agent AND is using in combination with carboplatin and atezolizumab AND has ECOG performance status 0‑2ECOG 0-2

    (NCCN 1, 2A)

    NSCLC - tremelimumab/durvalumab regimen: Individual has recurrent, advanced, or metastatic squamous NSCLC AND is using Abraxane as first‑line therapy with tremelimumab‑actl, durvalumab, and carboplatin AND has PD‑L1 expression ≥ 1% and ≤ 49% AND is not receiving systemic immunosuppressant therapy AND has ECOG performance status 0‑2PD‑L1 1-49%; ECOG 0-2

    (NCCN 2A)

    Ovarian cancer: Individual has epithelial ovarian, fallopian tube, or primary peritoneal cancer AND is using Abraxane as a single agent for persistent or recurrent disease OR with carboplatin if taxane hypersensitivity OR in combination with Lifyorli (relacorilant) for platinum‑resistant disease in those who have received 1–3 prior systemic regimens with at least one including bevacizumab

    (NCCN 1, 2A; FDA addition per document history)

    Pancreatic adenocarcinoma: Individual has metastatic adenocarcinoma of the pancreas AND is using Abraxane in combination with gemcitabine

    (Label, NCCN 1, 2A)

    Locally advanced pancreatic disease: Individual has locally advanced adenocarcinoma of the pancreas AND is using Abraxane in combination with gemcitabine as first‑line, subsequent, or continuation therapy

    (NCCN 2A)

    Endometrial carcinoma: Individual has endometrial carcinoma AND is using Abraxane as second‑line or subsequent therapy AND as a single agent

    (NCCN 2A)

    Vaginal cancer: Individual has locally advanced recurrent or metastatic vaginal cancer AND is using Abraxane as second‑line or subsequent therapy AND as a single agent

    (NCCN 2A)

    Small bowel adenocarcinoma: Individual has advanced or metastatic small bowel adenocarcinoma AND is using Abraxane as a single agent or in combination with gemcitabine as initial or subsequent therapy

    (NCCN 2A)

    Ampullary adenocarcinoma: Individual has ampullary adenocarcinoma (pancreatobiliary or mixed type) AND is using Abraxane in combination with gemcitabine AND has ECOG performance status 0‑2ECOG 0-2

    (NCCN 2A)

    Biliary tract cancer: Individual has biliary tract cancer AND is using Abraxane in combination with gemcitabine for unresectable disease, resected gross residual disease, or metastatic disease AND disease does not present with jaundice

    (NCCN 2A)

    Solid tumors with taxane hypersensitivity: Individual has a solid tumor for which taxane therapy is medically appropriate and has confirmed hypersensitivity to solvent‑based paclitaxel or docetaxel (NCCN 2A)

    Guideline/FDA-aligned coverage

    Policy aligns coverage with FDA approvals and NCCN guideline recommendations (various versions cited) for multiple tumor types and lines of therapy.

    Guideline and FDA-based coverage: Coverage decisions follow NCCN recommendations (including category 1 and 2A/2B where cited) and FDA‑approved indications as described in the document history and references.

    Full conditional logic and specific line‑of‑therapy criteria are detailed in the indication‑specific sections of this policy.

    Use of Abraxane for indications not explicitly listed in this policy may not be approved. Requests will be reviewed against the policy’s specified clinical groups and regimen-level criteria; if the requested indication is not described in those criteria, authorization is not expected to be granted.

    Per the document history, maintenance therapy for pancreatic adenocarcinoma was removed from the NCCN-based criteria and is no longer an approved indication under this policy. Providers requesting Abraxane for pancreatic disease should confirm the request matches current combination or line-of-therapy criteria (for example, use in combination with gemcitabine) rather than maintenance use.

    Requests for Abraxane that do not meet the policy’s listed coverage criteria are not medically necessary and will not be approved. Authorization decisions require demonstration that the patient meets the applicable indication-specific conditions and regimen/line-of-therapy requirements in the policy.

    Certain labeled contraindications are considered non-approvable under this policy. The document history notes inclusion of a baseline neutrophil count threshold among non-approvable criteria per the product labeling; requests for Abraxane that fail to meet such baseline neutrophil requirements will not be approved.

    Covered Regimens and Indication-Specific Combinations

    RegimenIndication / HistologyLine of Therapy / Key ConditionsCoverage Status
    {"text":"Abraxane + carboplatin + pembrolizumab","status":""}|{"text":"Recurrent, advanced, or metastatic squamous non–small cell lung cancer","status":""}|{"text":"First-line therapy; individual has ECOG 0-2","status":""}|{"text":"Covered","status":"covered"}
    {"text":"Abraxane + carboplatin + atezolizumab","status":""}|{"text":"Recurrent, advanced, or metastatic nonsquamous non–small cell lung cancer","status":""}|{"text":"First-line therapy; individual has ECOG 0-2","status":""}|{"text":"Covered","status":"covered"}
    {"text":"Abraxane + carboplatin + durvalumab + tremelimumab-actl","status":""}|{"text":"Recurrent, advanced, or metastatic squamous non–small cell lung cancer","status":""}|{"text":"First-line therapy; PD-L1 expression 1–49%; no sensitizing EGFR/ALK aberrations; not receiving systemic immunosuppressant; ECOG 0-2","status":""}|{"text":"Covered","status":"covered"}
    RegimenIndicationLine of Therapy / SettingCoverage Status
    {"text":"Abraxane + gemcitabine","status":""}|{"text":"Metastatic adenocarcinoma of the pancreas","status":""}|{"text":"First-line therapy for metastatic disease; also listed for locally advanced adenocarcinoma as first-line, subsequent, or continuation therapy","status":""}|{"text":"Covered","status":"covered"}
    RegimenIndication / BiomarkerLine of Therapy / Key ConditionsCoverage Status
    {"text":"Abraxane + pembrolizumab","status":""}|{"text":"Triple-negative breast cancer; PD-L1 positive","status":""}|{"text":"Combination use as first-line therapy (NCCN 1) or second/subsequent therapy if PD-1/PD-L1 inhibitor not previously used; prior conditions as specified in policy","status":""}|{"text":"Covered","status":"covered"}
    Regimen (examples)Context / Supporting NoteWhere to find specific regimen criteriaCoverage Status
    {"text":"Abraxane with carboplatin (various combinations)","status":""}|{"text":"Cited across document history and NCCN/FDA references for multiple tumor types (e.g., NSCLC, ovarian, biliary tract)","status":""}|{"text":"Specific regimen-level criteria and conditional requirements are detailed elsewhere in the policy (see COVERAGE CRITERIA and Document History entries)","status":""}|{"text":"Covered when policy criteria are met","status":"covered"}
    {"text":"Abraxane + Lifyorli (relacorilant) with carboplatin/platinum agents","status":""}|{"text":"FDA addition for use in combination for platinum‑resistant ovarian cancer per 06/08/2026 document history","status":""}|{"text":"See Document History entry 06/08/2026 and the ovarian cancer criteria section for regimen‑level conditions","status":""}|{"text":"Covered when policy criteria are met","status":"covered"}
    {"text":"Abraxane with pembrolizumab, atezolizumab, durvalumab, tremelimumab-actl (immune checkpoint combinations)","status":""}|{"text":"Used in select first-line and subsequent NSCLC and breast cancer settings aligned with NCCN or FDA guidance","status":""}|{"text":"Refer to the NSCLC and breast cancer sections for PD-L1 thresholds, ECOG requirements, and prior therapy conditions","status":""}|{"text":"Covered when policy criteria are met","status":"covered"}

    mixed

    Lines of therapy included: Policy specifies first‑line, second‑line, third‑line, fourth‑line and subsequent uses depending on cancer type and context (examples: first‑line NSCLC or pancreatic; second‑line cervical; fourth‑line HER2+ breast)

    See individual indication nodes for exact line‑of‑therapy requirements (e.g., HER2+ breast fourth‑line and beyond; ovarian platinum‑resistant per document history).

    first-line | second-line | salvage

    Line of therapy notes: Policy includes NCCN‑specified uses as first‑line, continuation, subsequent‑line, and fourth‑line and beyond for certain indications (for example: first‑line NSCLC combinations; first‑line or continuation pancreatic regimens; second‑line or subsequent use in cervical, endometrial, vaginal cancers; fourth‑line+ in HER2‑positive breast cancer)

    Specific definitions of first‑line/second‑line/etc. and any prerequisite therapies are provided in the indication‑specific criteria of the policy.

    Biomarker and Molecular Testing Requirements

    inv-25: PD-L1 — examples
    PD-L1 thresholdsExamples cited in policy: PD-L1 CPS <10 may guide first-line decisions in triple-negative breast cancer; PD-L1 1–49% required for the tremelimumab/durvalumab + carboplatin squamous NSCLC regimen.
    RolePD-L1 expression used to select immunotherapy-containing first-line regimens (TNBC and select NSCLC combinations).
    Decision impactLow or negative PD-L1 (e.g., CPS <10) can steer TNBC away from pembrolizumab-containing first-line use per policy conditions; intermediate PD-L1 (1–49%) is an explicit eligibility requirement for the tremelimumab/durvalumab carboplatin NSCLC regimen.
    inv-26: germline BRCA1/2
    Germline BRCA1/2 statusPolicy specifies first-line use in some TNBC contexts only if no germline BRCA1/2 mutation is present (i.e., first-line allowed when PD-L1 <10 and no germline BRCA1/2).

    Coding and Diagnosis Guidance

    Informational coding listmixed
    No codes listed
    Covered HCPCS Codes (informational)HCPCS
    J9264Injection, paclitaxel protein-bound particles, 1 mg [Abraxane]
    ICD-10 Diagnosis Codes (informational list)ICD-10
    C17.0-C17.9Malignant neoplasm of small intestine
    C22.1Intrahepatic bile duct carcinoma
    C23Malignant neoplasm of gallbladder
    C24.0-C24.9Malignant neoplasm of other and unspecified parts of biliary tract
    C25.0-C25.9Malignant neoplasm of pancreas
    C33Malignant neoplasm of trachea
    C34.00-C34.92Malignant neoplasm of bronchus and lung
    C43.0-C43.9Malignant melanoma of skin
    C46.0-C46.9Kaposi's sarcoma
    C48.0-C48.8Malignant neoplasm of retroperitoneum and peritoneum
    1–10 of 21
    1/3
    Covered HCPCS Codes (informational)HCPCS
    J9264Injection, paclitaxel protein-bound particles, 1 mg [Abraxane]
    ICD-10 Diagnosis Codes (informational list)ICD-10
    C17.0-C17.9Malignant neoplasm of small intestine
    C22.1Intrahepatic bile duct carcinoma
    C23Malignant neoplasm of gallbladder
    C24.0-C24.9Malignant neoplasm of other and unspecified parts of biliary tract
    C25.0-C25.9Malignant neoplasm of pancreas
    C33Malignant neoplasm of trachea
    C34.00-C34.92Malignant neoplasm of bronchus and lung
    C43.0-C43.9Malignant melanoma of skin
    C46.0-C46.9Kaposi's sarcoma
    C48.0-C48.8Malignant neoplasm of retroperitoneum and peritoneum
    1–10 of 21
    1/3
    inv-10: Baseline neutrophil count
    Baseline neutrophil count contraindicationDocument history notes addition of a baseline neutrophil count threshold to non-approvable criteria per labeled contraindications; exact numeric threshold not specified in excerpt.
    Policy effectRequests may be non-approvable if baseline neutrophil count falls below the policy's contraindication threshold (refer to labeled contraindications).
    DocumentationProviders should include baseline peripheral blood counts when seeking authorization due to neutropenia safety concerns.

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior authorization required; clinical criteria review

    Prior authorization is required; requests will be reviewed against the policy's clinical criteria and approved only for listed indications and conditions (for example: indication, line of therapy, ECOG performance status, prior therapies, and hypersensitivity status).

    Prior Authorization

    Prior authorization must include indication and coding

    Include the clinical indication and a supporting ICD-10 diagnosis code with prior authorization requests. Use the policy's listed HCPCS code for Abraxane (J9264) when submitting requests and claims.

    • HCPCS: J9264 (Injection, paclitaxel protein-bound particles, 1 mg) [[see coding]]
    Step Therapy

    Definitions and Key Concepts

    inv-20: ECOG performance status
    ECOG scaleECOG performance status is a 0–5 scale defining functional status (0 = fully active; 5 = dead).
    Common eligibility thresholdPolicy frequently requires ECOG 0–2 for eligible patients across multiple indications (examples include NSCLC and melanoma).
    Use in determinationsECOG score is used repeatedly in the policy to define patient fitness for first-line and subsequent regimens and to support medical necessity decisions.
    inv-21: Line of therapy
    First-line definitionFirst-line therapy: the first or primary treatment for the diagnosis; may include surgery, chemotherapy, radiation, or combination therapies.
    Subsequent-line definitionsSecond-line: treatment when initial therapy is not effective or disease progresses; Third-line: given when first- and second-line treatments are not effective.

    Background

    Abraxane is nanoparticle albumin-bound paclitaxel (a taxane). It is FDA-approved and used for multiple malignancies including metastatic breast cancer (after prior chemotherapy), first-line non-small cell lung cancer in combination with carboplatin for locally advanced or metastatic disease, and metastatic pancreatic adenocarcinoma in combination with gemcitabine. The policy aligns coverage with these FDA indications and with NCCN guidance for additional tumor types and lines of therapy.

    Revision History and Policy Changes

    2026-06-08select review / FDA additionLatest

    Added FDA indication for use in combination with Lifyorli (LifyoRli) for platinum‑resistant ovarian cancer and updated 'may not be approved' criteria; coding reviewed (no changes).

    2026-02-20annual review / NCCN alignment

    Added NCCN 2A criteria for fourth‑line and beyond use in HER2‑positive breast cancer and clarified multiple NCCN disease‑state criteria (melanoma, uveal melanoma, Kaposi sarcoma, endometrial, biliary tract) and removed pancreatic maintenance therapy; coding updated to add ICD‑10‑CM C50.A0–C50.A2 to the breast cancer range C50.011–C50.929.

    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyAbraxane (paclitaxel, protein bound) — Clinical Coverage Criteria
    Policy CodePolicy CC-0099
    Change TypeNCCN/FDA alignmentcoding and indication additions
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateJun 8, 2026
    Key ActionSubmit prior authorization with indication, relevant ICD-10 diagnosis code, ECOG status, prior therapies, and laboratory documentation (including baseline blood counts).
    SourceLink
    On This Page
    Coverage Criteria for Abraxane (paclitaxel, protein bound)Covered Regimens and Indication-Specific CombinationsBiomarker and Molecular Testing RequirementsCoding and Diagnosis GuidanceProvider Actions, Documentation, and AuthorizationDefinitions and Key ConceptsBackgroundRevision History and Policy Changes
    Effect on line selection
    Absence of germline BRCA1/2 can permit first-line Abraxane use in specific TNBC scenarios; presence of mutation influences alternative treatment selection per NCCN-aligned criteria.
    DocumentationProviders should document germline BRCA1/2 status when applying first-line TNBC criteria that reference this requirement.
    inv-27: EGFR/ALK
    EGFR/ALK testing requirementPolicy requires no sensitizing EGFR or ALK genetic tumor aberrations for certain squamous NSCLC first-line regimens (e.g., tremelimumab-actl + durvalumab + carboplatin).
    ContextAbsence of EGFR/ALK sensitizing aberrations is listed as a specific eligibility condition in squamous NSCLC first-line combinations.
    Provider actionDocument molecular testing showing no sensitizing EGFR or ALK aberrations when requesting coverage for the affected first-line squamous NSCLC regimens.

    Document required prior therapies for selected indications

    For certain indications (for example metastatic breast cancer) document prior receipt of specified therapies—such as prior combination chemotherapy and an anthracycline unless contraindicated—before approval will be granted.

    • Metastatic breast cancer examples: prior combination chemotherapy and prior anthracycline unless contraindicated (per breast cancer criterion language).
    Step Therapy

    Follow guideline-based line-of-therapy sequencing

    The policy aligns with NCCN and FDA-referenced sequencing; adherence to guideline-specified line-of-therapy sequencing (first-line, subsequent lines, fourth-line and beyond where specified) is implied for approval decisions.

    • Example: HER2‑positive breast cancer — coverage added for fourth-line therapy and beyond in combination with trastuzumab per NCCN 2A (document history).
    • Example: TNBC — first-line versus second-line use determined by PD‑L1 and germline BRCA1/2 status per NCCN nodes.
    Documentation Required

    Required clinical and laboratory documentation (ANC, prior chemo, biomarkers)

    Document baseline and follow-up peripheral blood cell counts because Abraxane's label includes a black box warning for neutropenia (baseline ANC < 1,500 cells/mm3 contraindicates use). Also document prior chemotherapy history and relevant tumor biomarker or hypersensitivity status to support indication-specific criteria.

    • Baseline ANC and frequent peripheral blood cell counts to monitor for bone marrow suppression (black box warning).
    • Prior chemotherapy details (e.g., prior anthracycline in breast cancer) and tumor biomarker results (PD‑L1, germline BRCA1/2, EGFR/ALK where applicable).
    • Document confirmed taxane hypersensitivity when that is the basis for using Abraxane.
    Documentation Required

    Include a listed ICD-10 diagnosis code with the request

    When requesting coverage, specify an applicable ICD‑10 diagnosis code from the policy's listed ranges to support medical necessity (use one of the listed codes that matches the member's diagnosis).

    • Examples of listed ranges: C17.0‑C17.9; C25.0‑C25.9; C34.00‑C34.92; C50.011‑C50.A2; and other codes in the policy's ICD‑10 list.
    Denial Risk

    Potential denial when coverage criteria are unmet

    If the request does not meet the policy's listed coverage criteria, Abraxane will not be approved; requests for indications not explicitly listed are not approved.

    Billing Rule

    Coding mismatch risk if HCPCS not J9264

    Use the policy-listed HCPCS code J9264 for Abraxane; claims submitted with other HCPCS codes that are not listed in the policy may trigger coding review or denial for coding mismatch.

    • CMS coding history notes removal of other HCPCS (J9258, J9259) and policy lists J9264 as the covered code.
    Policy usagePolicy specifies first-, second-, third-, and fourth-line (and beyond) uses depending on cancer type (examples: first-line NSCLC or pancreatic; second-line cervical; fourth-line HER2+ breast).
    inv-22: Abraxane
    Product descriptionAbraxane = paclitaxel protein-bound particles (nanoparticle albumin-bound paclitaxel).
    HCPCS codeHCPCS J9264 — Injection, paclitaxel protein-bound particles, 1 mg [Abraxane].
    Billing noteUse HCPCS J9264 to align claims with the policy's coding guidance for Abraxane-related prior authorization and claims processing.
    2025-02-21annual review / NCCN additions and coding

    Added NCCN 2A Kaposi sarcoma and NCCN 2A vaginal cancer recommendations; clarified cervical and pancreatic recommendations and removed broader ICD‑10 ranges and D00.0‑D09.9; CMS coding update on 11/25/2024 removed HCPCS J9258 and J9259.

    2024-02-23annual review / regimen and coding update

    Updated criteria for breast, pancreatic, and small bowel adenocarcinoma; added NCCN 2A biliary tract and cervical cancer recommendations; coding reviewed and HCPCS J9258 added.

    2023-02-24annual review / NCCN additions and coding

    Added NCCN 2A criteria for small bowel and ampullary adenocarcinomas and for recurrent advanced/metastatic squamous NSCLC in combination with tremelimumab‑actl, durvalumab, and carboplatin; coding updated to add HCPCS J9259 and ICD‑10‑CM C17.0‑C17.9 and C24.1.

    2024-02-23regimen-level change

    Documented regimen‑level additions including NCCN 2A biliary tract cancer use with gemcitabine and other regimen clarifications for breast and pancreatic disease; coding noted addition of HCPCS J9258.

    2023-02-24regimen-level change

    Added regimen‑level language for recurrent, advanced, or metastatic squamous NSCLC in combination with tremelimumab‑actl, durvalumab, and carboplatin; coding updated to add HCPCS J9259.

    2021-05-21regimen-level change

    Updated criteria to allow use of Abraxane in combination with pembrolizumab for triple‑negative breast cancer per NCCN guidance.

    2021-09-13regimen-level change

    Removed use with atezolizumab for triple‑negative breast cancer following FDA withdrawal; coding ranges for relevant diagnoses were extended.

    2020-05-15regimen-level change

    Updated NSCLC criteria to include first‑line therapy use in recurrent and advanced disease and added specificity about mutation confirmation when used with atezolizumab and carboplatin.